Korea’s ethical markets getting heated

Competition is about to heat up in the domestic ethical drug markets, as Gilead Sciences’ Viread (tenofovir), Boehringer Ingelheim’s Trajenta (linagliptin) and AstraZeneca’s Brilinta (tigagrelor) are expanding their shares of the domestic drug markets dominated by foreign forerunners.

Market experts predicted that Viread’s sales will exceed 10 billion won this year, thanks to Yuhan’s extensi...